Peggy Gilmour

Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.

Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.